Nektar Therapeutics
NKTR
Delayed Nasdaq - 06/22 10:00:00 pm
52.85USD
-5.39%
Prev.55.8600
Open56.1000
High56.1950
Low52.8400
Volume21 720 134
Financials
Sales 2018 1 179 M
EBIT 2018 669 M
R. net 2018 620 M
Debt 2018 -
Rend. 2018 -
P/E ratio 2018 14,97
P/E ratio 2019
Capi. / Sales 2018 8,46x
Capi. / Sales 2019 36,1x
Capitalization 9 970 M
Company
Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms.It operates through the United States and Europe geogrpahical segments.The company was founded in 1990 and is...
Sector :
Biotechnology & Medical Research - NEC
Calendar :
2018-06-26 Shareholder meeting
Trading Rating :
Investor Rating :
Latest news
06/22NEKTAR THERAPEUTICS : U.S. Patents Awarded to Inventors in Alabama (June 22)
AQ
06/21NEKTAR THERAPEUTICS : New Data for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy, Presented at...
AQ
06/14NEKTAR THERAPEUTICS : New Data for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy, Presented at College on Problems of Drug Dependence 80th Annual Scientific Meeting
PR
06/08FRIDAY 6/8 INSIDER BUYING REPORT : Yumc, nktr
AQ
06/07SYNDAX PHARMACEUTICALS : and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration
AQ
06/07NEKTAR THERAPEUTICS : Entry into a Material Definitive Agreement (form 8-K)
AQ
06/06NEKTAR THERAPEUTICS : Bristol-Myers Squibb - Preliminary Data for NKTR-214 in Combination with Opdivo for Patients with Stage IV Metastatic Melanoma
AQ
06/05NEKTAR THERAPEUTICS : to Webcast Presentation at the Jefferies 2018 Healthcare Conference in New York
PR
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishBearishBullish
Resistance69,477,2108
Spread/Res.-24%-32%-51%
Spread/Supp.0,53%0,53%23%
Support52,652,643,0